Clinical trial analysis identifies biomarker cohorts for bevacizumab response in progressive glioblastoma, highlighting candidate profiling feasibility.
Supplementary Figure 1: Overview of the clinical trial and biomarker analysis. Out of 596 patients in the EORTC-26101 trial, patient tumor tissue to perform DNA methylation (Meth) and NGS sequencing analysis was available from 380 patients (63.8%). Of these, 99 patients treated with lomustine and 189 patients treated with lomustine and bevacizumab were eligible to detect biomarkers for bevacizumab response.
No takes yet. Share an insight, caveat, or question.
Keßler et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: